Keyphrases
Antipsychotics
16%
Brief Psychiatric Rating Scale
33%
Cannabinoid Receptor 1 (CB1R)
16%
CB1 Antagonist
16%
Change from Baseline
16%
Clinical Global Impression
33%
Control Evaluation
100%
Endpoint Analysis
16%
Evidence-based
16%
Fixed-dose Combination
16%
Haloperidol
50%
Investigational Drugs
33%
Negative Syndrome
50%
Neurokinin B
16%
Neurotensin
16%
NK3 Antagonist
33%
Non-dopaminergic
16%
Novel Design
16%
NTS1
33%
Number of Patients
16%
Placebo
100%
Placebo-controlled
100%
Plasma Parameters
16%
Psychopathology
16%
Psychosis
33%
Schizoaffective Disorder
100%
Schizophrenia Symptoms
100%
Schizophrenia Treatment
100%
Serotonin 2A
16%
Serotonin 2A Receptor (5-HT2AR)
66%
Severity of Illness Score
33%
SR141716
16%
SR142801
16%
SR48692
16%
Pharmacology, Toxicology and Pharmaceutical Science
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
42%
Antipsychotic
14%
Cannabinoid
14%
Diseases
28%
Eplivanserin
14%
Investigational Drug
28%
Meclinertant
14%
Negative Syndrome
42%
Neurokinin
14%
Neurokinin 3 Receptor Antagonist
28%
Neurotensin
14%
Osanetant
14%
Placebo
100%
Positive Syndrome
42%
Rimonabant
14%
Schizoaffective Psychosis
100%
Serotonin
14%
Neuroscience
Antipsychotic
14%
Blood Plasma
14%
Cannabinoid
14%
Haloperidol
42%
Negative Syndrome
42%
Neurokinin
14%
Neurotensin
14%
Placebo
100%
Positive Syndrome
42%
Rimonabant
14%
Schizoaffective Disorder
100%
Serotonin
14%
Treatment of Schizophrenia
100%